Pre- and Post-natal Blarcamesine Developmental Defect Prophylaxis
It is now well-demonstrated that blarcamesine, by its activation of the sigma-1 receptor protein, favorably modulates or promotes a number of propitious cell-keeping processes, the ones involved in autophagy, the multitude of processes within cells that remove cellular wastes and maintain internal cell processes. The term autophagy, from auto-, meaning “self,”and -phagy, meaning “to eat,” is where the cell eats itself; but consumes only the cell’s internal wastes, toxins, or non-functioning organelles. Autophagy is the cell’s essential internal cleanup processes.
But, as organisms age, autophagic processes decline. Age-related pathologies thereby increase. Hence, there is the prospect that the administration of blarcamesine in late middle age will maintain age-inhibiting autophagy, prophylactically yielding fewer age-related diseases. As I’ve indicated before, Anavex surely has clinical data on this, derived from typical aging studies done in certain lab organisms, such as the lab roundworm Ceanorhabtidis elegans. There is the eventual prospect that blarcamesine or Anavex 3-71 will be typically and commonly prescribed for and taken by everyone, to safely and effectively maintain autophagic processes; to thereby improve and maintain health throughout life.
But blarcamesine induces other favorable cell processes. One is involved in gene expression, where genes in chromosomes have the chromatin surrounding them chemically unwrapped, allowing the now freed-up gene, a length of DNA, to be transported to a ribosome where the genetic information produces a specific protein. Those proteins are specific enzymes that catalyze subsequent chemical reactions that enliven the cell.
Key is this. Gene expression, the converting of the DNA of specific genes to cellular chemicals that make the cell function, must be an error-free and efficient process. If gene expression goes wholly wrong, the cell dies. But fractional or partial gene expression is merely pathogenic. The cell and the organ system in which it resides continues to function, but in a diseased state. Such is the case with the neurons involved in Alzheimer’s disease.
But here is a new, but related blarcamesine conjecture — one that I’m certain Anavex has confirmatory data on but has the good sense to keep quiet about. At the right time, it will be an Anavex media announcement; but most likely after blarcamesine is already approved as a CNS disease therapy.
The conjecture is this: that blarcamesine may prove to be a safe, effective, and inexpensive birth defect prophylactic. Many birth defects are caused by erroneous gene expression starting with the growth of the embryo, right after egg is fertilized, before the mother even knows she’s pregnant. Therefore, women desiring to have a baby would be prescribed a daily dose of blarcamesine, which would diffuse into the egg, before conception, and be available to implement fully functional autophagy and gene expression, starting right in the zygote, the one-celled fertilized egg. The mother would continue to take blarcamesine through her entire pregnancy, during which the zygote, then the embryo, then the fetus, and then the infant would develop with minimized chances of defects caused by compromised gene expression.
But, of course, gene expression doesn’t terminate at birth. During a child’s physical development, all sorts of genetic or physiological problems can occur — many of which might well be obviated by the presence of daily or weekly doses of blarcamesine.
Blarcamesine prophylaxis — from conception through all of life.
